Learn the key strategies adopted by leading CDMO Syngene to accelerate the lead to first-in-human (FIH) journey of small molecules for clients.

Learn the challenges in the detection and quantitation of process-related impurities, including nitrosamine and azido impurities, and Syngene’s capabilities and solutions to resolve them.

Learn how Syngene provides in silico and in vitro support for holistic toxicity assessment using Computational & Data Sciences.

Learn the role of biophysics-driven analytical tools in accurately identifying biologics CQAs and analyzing HOS to make the final product efficacious and safe for patients from a regulatory perspective.

Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.

Learn how Syngene is helping pharma companies minimize environmental impact using its Green Chemistry approach to drug development.

Learn how Syngene built a biopharma supply chain that is fast, resilient, and future-proof and, in the process, turned supply chain risks into a competitive advantage.

Learn how Syngene is achieving three to four-fold higher titers of mAbs using its Intensified Fed-Batch process

Comprehensive diligence around a target at the start of a discovery program can make the difference between success and failure. Learn how Syngene’s Target Assessment service enables informed decision-making resulting in increased clinical and commercial success.

Learn about Syngene’s expertise in  Safety/Tox studies that allows us to guide you through the various requirements leading to successful IND submission.